Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
255.4 CHF | -1.31% | +2.65% | -2.30% |
May. 22 | Roche: FDA designation for blood test | CF |
May. 22 | Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test | MT |
Sales 2024 * | 60.06B 65.65B | Sales 2025 * | 63.61B 69.53B | Capitalization | 187B 205B |
---|---|---|---|---|---|
Net income 2024 * | 13.41B 14.66B | Net income 2025 * | 14.87B 16.25B | EV / Sales 2024 * | 3.35 x |
Net Debt 2024 * | 13.78B 15.06B | Net Debt 2025 * | 7.77B 8.5B | EV / Sales 2025 * | 3.07 x |
P/E ratio 2024 * |
13.5
x | P/E ratio 2025 * |
12.3
x | Employees | 103,605 |
Yield 2024 * |
4.19% | Yield 2025 * |
4.34% | Free-Float | 88.91% |
Latest transcript on Roche Holding AG
1 day | -1.31% | ||
1 week | +2.65% | ||
Current month | +6.06% | ||
1 month | +4.59% | ||
3 months | +4.50% | ||
6 months | +2.41% | ||
Current year | -2.30% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 02-12-31 | |
Severin Schwan
CHM | Chairman | 57 | 07-12-31 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 11-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 15-03-02 |
Director/Board Member | 59 | - | |
Director/Board Member | 66 | 95-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.06% | 2 M€ | +9.19% | - | |
2.06% | 2 M€ | -.--% | - | |
0.84% | 17 M€ | 0.00% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-22 | 255.4 | -1.31% | 39,656 |
24-05-21 | 258.8 | +0.23% | 33,732 |
24-05-17 | 258.2 | +0.55% | 24,497 |
24-05-16 | 256.8 | +3.22% | 39,828 |
24-05-15 | 248.8 | +1.47% | 20,571 |
Delayed Quote Swiss Exchange, May 22, 2024 at 11:30 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.74% | 723B | |
+32.22% | 598B | |
-2.07% | 364B | |
+20.25% | 331B | |
+2.99% | 288B | |
+16.60% | 244B | |
+9.77% | 210B | |
+7.43% | 169B | |
+2.81% | 162B |
- Stock Market
- Equities
- ROG Stock
- RO Stock